Global Markets Direct's latest Pharmaceutical
and Healthcare disease pipeline guide Spinocerebellar Ataxia (SCA) - Pipeline
Review, H1 2018, provides an overview of the Spinocerebellar Ataxia (SCA)
(Genetic Disorders) pipeline landscape.
Spinocerebellar
Ataxias (SCA)
are a group of inherited conditions that affect the brain and spinal cord
causing progressive difficulty with coordination. Symptoms include poor
coordination, unsteady walk and a tendency to stumble, change in speech and
difficulty swallowing.
Global Markets Direct's Pharmaceutical and
Healthcare latest pipeline guide Spinocerebellar Ataxia (SCA) - Pipeline
Review, H1 2018, provides comprehensive information on the therapeutics under
development for Spinocerebellar Ataxia (SCA) (Genetic Disorders), complete with
analysis by stage of development, drug target, mechanism of action (MoA), route
of administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.
The Spinocerebellar Ataxia (SCA) (Genetic
Disorders) pipeline guide also reviews of key players involved in therapeutic
development for Spinocerebellar Ataxia (SCA) and features dormant and
discontinued projects. The guide covers therapeutics under Development by
Companies /Universities /Institutes, the molecules developed by Companies in
Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 1, 4
and 2 respectively. Similarly, the Universities portfolio in Phase III,
Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively.
Spinocerebellar Ataxia (SCA) (Genetic Disorders)
pipeline guide helps in identifying and tracking emerging players in the market
and their portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage. The guide is built
using data and information sourced from Global Markets Direct's proprietary
databases, company/university websites, clinical trial registries, conferences,
SEC filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources.
Additionally, various dynamic tracking processes ensure that the most recent
developments are captured on a real time basis.
The pipeline guide provides a snapshot of the
global therapeutic landscape of Spinocerebellar Ataxia (SCA) (Genetic
Disorders).
The pipeline guide reviews pipeline
therapeutics for Spinocerebellar Ataxia (SCA) (Genetic Disorders) by companies
and universities/research institutes based on information derived from company
and industry-specific sources.
The pipeline guide covers pipeline products
based on several stages of development ranging from pre-registration till
discovery and undisclosed stages.
The pipeline guide features descriptive drug
profiles for the pipeline products which comprise, product description,
descriptive licensing and collaboration details, R&D brief, MoA & other
developmental activities.
The pipeline guide reviews key companies
involved in Spinocerebellar Ataxia (SCA) (Genetic Disorders) therapeutics and
enlists all their major and minor projects.
The pipeline guide evaluates Spinocerebellar
Ataxia (SCA) (Genetic Disorders) therapeutics based on mechanism of action
(MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the
dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related
to pipeline therapeutics for Spinocerebellar Ataxia (SCA) (Genetic Disorders)
To know more, click on the link below:
Related Reports:
Contact Us:
Ken
Research
Ankur
Gupta, Head Marketing & Communications
0124-4230204